To evaluate safety and tolerability after multiple oral doses of AZD1656 in type 2 diabetes patients on top of metformin
Study identifier:D1020C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in subjects with T2DM treated with Metformin
Medical condition
Type 2 Diabetes
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1656, Placebo
Sex
All
Actual Enrollment
70
Study type
Interventional
Age
30 Years - 75 Years
Date
Study Start Date: 01 Oct 2008
Primary Completion Date: -
Study Completion Date: 01 Jan 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD1656 | Drug: AZD1656 Dose titration of oral suspension to a tolerable dose given twice daily for 10 days. |
| Placebo Comparator: 2 Placebo | Drug: Placebo Dose titration of oral suspension to a tolerable dose given twice daily for 10 days. |
Contacts
Investigators
Principal Investigator
Klas Malmberg
AstraZeneca R&D Mölndal
